Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.
Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.
Immunology. 2024 Dec;173(4):634-653. doi: 10.1111/imm.13861. Epub 2024 Sep 28.
The remarkable success of mRNA-based coronavirus 2019 (COVID-19) vaccines has propelled the advancement of nanomedicine, specifically in the realm of RNA technology and nanomaterial delivery systems. Notably, significant strides have been made in the development of RNA-based in vivo chimeric antigen receptor (CAR) therapy. In comparison to the conventional ex vivo CAR therapy, in vivo CAR therapy offers several benefits including simplified preparation, reduced costs, broad applicability and decreased potential for carcinogenic effects. This review summarises the RNA-based CAR constructs in in vivo CAR therapy, discusses the current applications of in vivo delivery vectors and outlines the immune cells edited with CAR molecules. We aim for the conveyed messages to contribute towards the advancement of in vivo CAR application.
mRNA 冠状病毒 2019（COVID-19）疫苗的显著成功推动了纳米医学的发展，特别是在 RNA 技术和纳米材料传递系统领域。值得注意的是，RNA 体内嵌合抗原受体（CAR）疗法的发展取得了重大进展。与传统的体外 CAR 疗法相比，体内 CAR 疗法具有许多优势，包括简化制备、降低成本、广泛适用性和降低致癌作用的潜力。本综述总结了体内 CAR 疗法中的 RNA 基 CAR 构建体，讨论了体内传递载体的当前应用，并概述了用 CAR 分子编辑的免疫细胞。我们的目标是传达信息，促进体内 CAR 应用的发展。
